Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20877709 | 1.00 | DPP4 (0.46) | DPP4EPHX1DPP7KCNH2DPP8 | |
| SCHEMBL18401046 | 1.00 | DPP4 (0.46) | DPP4EPHX1DPP7KCNH2DPP8 | |
| SCHEMBL8013071 | 0.98 | DPP4 (0.49) | DPP4EPHX1DPP7KCNH2DPP8 | |
| SCHEMBL14886200 | 0.91 | ALOX5 (0.40) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL12937984 | 0.91 | ALOX5 (0.40) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL10140621 | 0.91 | ALOX5 (0.40) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL12282426 | 0.81 | PIK3CD (0.36) | DPP4 | |
| SCHEMBL12462754 | 0.81 | PIK3CD (0.36) | DPP4 | |
| SCHEMBL9252192 | 0.79 | EPHX1 (0.38) | EPHX1 | |
| SCHEMBL24063542 | 0.78 | DPP4 (0.44) | DPP4EPHX1DPP7KCNH2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | DPP4 1492/4885EPHX1 1220/4885DPP7 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.